Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients - Summary - MDSpire
Advertisement
Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients
To compare the response assessment of iRECIST and RECIST 1.1 in patients with NSCLC and melanoma treated with immune checkpoint inhibitors, highlighting the clinical significance of this comparison in a real-world setting.
Key Findings:
iRECIST may better accommodate atypical tumor response patterns like pseudoprogression compared to RECIST 1.1, potentially reducing premature treatment discontinuation.
Limited evidence exists on the real-world advantages of iRECIST over RECIST 1.1, necessitating further investigation.
Previous studies on iRECIST are often limited by small sample sizes and single tumor types, indicating a need for larger, more diverse studies.
Interpretation:
The study underscores the necessity for standardized response assessment criteria that accurately reflect treatment responses in patients receiving immune checkpoint inhibitors.
Limitations:
The study is retrospective and conducted at a single center, which may introduce biases.
Findings may not be generalizable to all patient populations or settings.
Conclusion:
Further research is essential to validate the effectiveness of iRECIST in real-world settings and its potential superiority over RECIST 1.1 for assessing treatment responses in ICI therapy.
by Christian Nelles, Moritz Gräf, Pascale Bernard, Thorsten Persigehl, Nils Große Hokamp, David Zopfs, David Maintz, Nicole Kreuzberg, Jürgen Wolf, Paul J. Bröckelmann, Simon Lennartz
